OS Therapies (NYSEAMERICAN:OSTX) Issues Earnings Results

OS Therapies (NYSEAMERICAN:OSTX) announced its quarterly earnings results on Tuesday. The company reported ($0.41) earnings per share for the quarter, FiscalAI reports.

OS Therapies Stock Performance

NYSEAMERICAN:OSTX opened at $1.33 on Tuesday. OS Therapies has a 52-week low of $1.12 and a 52-week high of $2.57. The stock has a fifty day moving average of $1.40 and a 200 day moving average of $1.66. The firm has a market capitalization of $46.83 million, a price-to-earnings ratio of -1.62 and a beta of -3.80.

Institutional Trading of OS Therapies

Several institutional investors and hedge funds have recently modified their holdings of the business. CM Management LLC boosted its position in shares of OS Therapies by 6.7% during the 3rd quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $784,000 after acquiring an additional 25,000 shares during the last quarter. Geode Capital Management LLC increased its position in shares of OS Therapies by 31.1% in the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after purchasing an additional 58,350 shares during the last quarter. Millennium Management LLC purchased a new stake in OS Therapies in the third quarter valued at approximately $183,000. Two Sigma Investments LP purchased a new stake in OS Therapies in the third quarter valued at approximately $169,000. Finally, Virtu Financial LLC lifted its position in OS Therapies by 252.0% during the third quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after purchasing an additional 54,269 shares during the last quarter.

Analyst Ratings Changes

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a research note on Friday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.50.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.